Axogen Inc vs SPDR Gold Trust — how do they compare? Axogen Inc trades at $49.23 (market cap $2.61B), while SPDR Gold Trust trades at $404.73. The key difference: Axogen Inc is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals.
| AXGN | GLD | |
|---|---|---|
Market Cap | $2.61B | — |
Sector | Technology | — |
52-Week High | $48.48 | $495.90 |
52-Week Low | $14.16 | $305.27 |
Enterprise Value | $2.52B | — |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.10, up 1.82% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth (23.1% in Q2 2026) and raised full-year guidance to $279 million, though profitability remains negative with a -13.36% net margin. Technical indicators show overbought RSI levels but strong moving average support, while institutional ownership and analyst consensus (84% buy ratings) signal confidence in the company's nerve care platform expansion.
The outlook remains positive given strong revenue momentum and regulatory advantages, but investors face execution risks from persistent losses and high valuation multiples. Upside potential exists toward the $54.33 consensus target if margin improvements materialize, though volatility may persist near current resistance levels.
GLD trades at $403.80, up 0.29% with bullish technical signals from moving averages and strong momentum indicators. The ETF benefits from recent inflation data showing cooling CPI pressures and heightened geopolitical tensions driving safe-haven demand. Recent news highlights gold's resilience amid Federal Reserve policy uncertainty and strong central bank buying activity.
Outlook remains positive with technical resistance at $405-$407 and support at $399-$401. Key risks include potential Fed policy shifts and dollar strength, while catalysts include sustained inflation concerns and geopolitical instability. The ETF's momentum suggests potential for further gains toward resistance levels.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →